Treatment of Tinea Capitis in Infants
For infants with tinea capitis, oral griseofulvin at 15-20 mg/kg/day for 6-8 weeks is the first-line treatment, as it is the only licensed systemic antifungal for children as young as 1 month of age in the U.K. and has extensive safety data in this age group 1.
Treatment Algorithm Based on Age and Pathogen
For Infants ≥1 Month Old:
First-line therapy:
- Griseofulvin 15-20 mg/kg/day (single or divided dose) for 6-8 weeks 1
Species-specific considerations:
- If Trichophyton species confirmed: Consider terbinafine (off-label in infants <20 kg: 62.5 mg/day for 2-4 weeks), though unlicensed in this age group 1
- If Microsporum species confirmed: Continue griseofulvin (superior efficacy) 1
Second-line therapy (if first-line fails):
For Newborns <1 Month Old:
This represents a special clinical scenario with limited evidence. The 2014 British guidelines specify griseofulvin is licensed from 1 month of age 1, creating a therapeutic gap for younger infants.
Treatment options based on recent case reports:
- Topical antifungal monotherapy may be attempted first in newborns, as successful cases have been reported 4, 5
- If systemic therapy required: Itraconazole oral solution pulse therapy has demonstrated safety and efficacy in infants as young as 23-24 days 3, 4
- A 2024 U.S. survey showed pediatric dermatologists prefer fluconazole for infants 0-2 months 6
Critical Management Points
Always initiate oral systemic therapy—topical therapy alone is insufficient 1. The British Association of Dermatologists gives this a Strength A recommendation. Topical agents cannot penetrate the hair follicle adequately to eradicate infection, though they reduce spore transmission.
When to start treatment:
- If kerion present OR cardinal signs (scaling, lymphadenopathy, alopecia): Start treatment immediately without waiting for culture 1
- Culture results take 2-4 weeks; delaying treatment increases transmission risk
Adjunctive topical therapy: Add antifungal shampoo (ketoconazole 2%, selenium sulfide 1%, or povidone-iodine) to reduce spore transmission 1
Common Pitfalls and How to Avoid Them
Species matters for drug selection: Terbinafine fails against Microsporum in prepubertal children because it's not excreted in sweat/sebum and cannot reach the scalp surface where Microsporum arthroconidia reside 1. Always use griseofulvin for Microsporum infections.
Treatment endpoint is mycological cure, not clinical improvement: Continue therapy until repeat mycology is negative 1. Clinical improvement with persistent positive cultures requires extending treatment 2-4 weeks 1.
Consider treatment failure causes: Non-compliance, suboptimal drug absorption, organism resistance, or reinfection 1. If no clinical improvement, switch to second-line therapy rather than extending current regimen.
Screen household contacts: For T. tonsurans cases, screen and treat all family members and close contacts 1. Asymptomatic carriers with high spore loads require systemic treatment 1.
Contraindications to Griseofulvin
Avoid in infants with lupus erythematosus, porphyria, or severe liver disease 1. Drug interactions: rifampicin decreases levels; cimetidine increases levels 1.
Practical Considerations for Infants
- Griseofulvin suspension (though increasingly expensive and no longer licensed in some regions) allows accurate dosing adjustments in small infants 1
- Itraconazole oral solution is more practical than tablets for weight-based dosing in infants 2, 3
- Infants on appropriate therapy can attend daycare/nursery 1